Colorectal cancer refers to the cancer that occurs in the colon and rectum. It 
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer involving 2.4 million people per year worldwide. According to the age-standardized rate, the incidence of colorectal cancer in Malaysia showed higher occurrence in men by 20.9 cases per 100,000 compared to in women at 16.8 per 100,000 populations (Chye et al. 2008) . Majority of the cases occurred in Chinese ethnic followed by the Malays and Indians (Radzi et al. 2016) . Dietary habit has been listed as a main factor that affects intestinal macro and microenvironment. Consumption of food that affects the intestinal lining gave rise to the development of polyps. It was due to the harmful chemicals that are able to penetrate the cells and disturb genome stability by a process known as mutation (Kanner 2007; O'Keefe 2016; Ryan-Harshman & Aldoori 2007) . The examples of bad dietary habit include consumption of carcinogenic foods, lack of dietary fiber in the diet that lead to the intestinal bleeding as well as a disturbance to the microbiome environment and probiotic metabolisms (Louis et al. 2014) .
Consumption of food high in fiber enables gut microbiota to produce short-chain fatty acid such as butyrate during fermentation. Butyrate has an antiinflammatory and antineoplastic properties; and it can also provide the best energy source for colonocytes. Therefore, the risk of intestinal bleeding will be reduced as inflammation is suppressed by the anti-inflammatory substances produced by gut microbiota. Imbalance diet such as high consumption of protein and fat will produce substances with carcinogenic effects such as branched fatty acids that may induce inflammation and hydrogen sulfide that could cause DNA damage and lead to mutation if the repair mechanism is disrupted (O'Keefe 2016). These mutations may eventually affect the genes that are 3096 necessary to regulate cellular growth and to maintain the balance of cell proliferation.
Cancer driver genes are defined as genes that provide selective advantage for the cell to grow more rapidly as the proliferation and death-escaping characteristics of the cell are enhanced. These properties enable cells to grow more rapidly than their neighbouring cell in a specific condition and environment (Tokheim et al. 2016) . Cancer driver genes such as APC (adenomatous polyposis coli) gene plays a critical role in regulating Wnt signaling pathway that responsible for cell proliferation. APC forms a destruction complex with several other proteins to inhibit ß-catenin, a protein that activates Wnt signaling and preventing the cells to proliferate continuously. Mutation in APC may affect its function to perform destruction complex and unable to control cell proliferation (Kwong & Dove 2009; Zhan et al. 2017) . Driver genes can be mutated at both protein coding and non-coding regions but more commonly at the protein coding region. This mutation causes abnormal function of the genes and is known as driver mutation (Foo et al. 2015) . The term 'driver' is introduced to distinguish it from a passenger gene that does not contribute to any abnormal cell growth. Passenger genes could be any genes or recorded as driver genes in TCGA database, however does not carry any driver mutation that affect their structure and function (Marx 2014) .
Identification of cancer driver genes is one of the important aspects in whole genome sequencing projects. Two prominent consortiums working on the collection of cancer genes data are Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC). The top driver genes that currently reported contribute to colorectal carcinogenesis are APC, TP53 and KRAS. APC acts as tumor suppressor that form 'destruction complex' with Axin and GSK-3β to degrade β-Catenin in Wingless (Wnt) signaling pathway. Mutation which could lead to loss function of APC allows β-catenin keep acting as signal to promote cell proliferation through Wnt signaling pathway (Alberts 2008; Kwong & Dove 2009 ). TP53 is activated by cellular stresses including DNA damage and acts as tumor suppressor that bind to regulatory regions of downstream target genes to induce cell cycle arrest, DNA repair and apoptosis (Iacopetta et al. 2006) . Inactivation of TP53 is associated with later stage in cancer as the role of TP53 as an important upstream key regulator to control the number of cancer cells through apoptosis become malfunction (Rivlin et al. 2011) . Proto-oncogene is a gene that normally has a role in activating or continuing cell proliferation, growth and differentiation activity. Mutation in this type of genes could lead to gain of function and transform proto-oncogenes to new role in driving cancer known as oncogenes. Oncogene such as KRAS could drive the cancer through mutation at specific binding sites. This could prevent KRAS to degrade and enable the pathways continuously run to induce cell growth and proliferation.
Precision medicine in cancer requires the information of cancer driver genes in order to perform specific therapy to target altered function of component in signaling pathways. Genes like KRAS has been targeted through biologic agents like cetuximab and panitumumab in clinical trials (Tan & Du 2012) .
Various bioinformatics tools for driver genes prediction have been developed to provide analysis tools for tumor sequencing project to distinguish driver and passenger genes; amongst other are SIFT (Sorting Intolerants from Tolerant) and Polyphen 2 (Polymorphism Phenotyping v2) (Adzhubei et al. 2015; Sim et al. 2012 ), HotNet2, MUFFINN (Mutations For Functional Impact on Network Neighbors) (Cho et al. 2016; Leiserson et al. 2014) and MuSIC (Mutational Significance in Cancer) (Dees et al. 2012) . Here, two computational methods were used, i.e. Integrated Cancer Genome Score (iCAGES) and Cancer Genome interpreter (CGI). Both tools allowed for a single patient-based data analysis in determining high confidence prediction on driver genes via a combination of different tools that use different concept of systematic approaches.
iCAGES analyses the impact of variants using the scores obtained from eleven prediction tools that predict the impact of variants on the protein structure and function. Identification of cancer driver genes uses radial support vector machine (radial svm), a machine learning algorithm that combines all scores from the prediction tools. These tools were SIFT, PolyPhen 2, GERP++, Mutation Assessor, SiPhy, LRT, PhyloP, FATHMM, Mutation Tester, CADD and VEST. Driver gene prioritization unified radial SVM score with other bioinformatic tool known as Phenolyzer that predicts driver genes based on the oncogenicity of point coding mutation. Linear regression (LR) model is built to determine driver gene score with 0.11 as binary cut off for suggested cancer driver genes.
CGI determine the characteristics of cancer driver genes through the classification of genes based on their tumorigenic mode (Oncogene or Tumor Suppressor). Functional impact according to types of mutation, and occurrence among human population. CGI search and match query variants with TCGA database of cancer genes. Variants with no matches in TCGA library will undergo protein affecting mutation (PAM) assessment by algorithm known as Oncodrive-MUT. Oncodrive-MUT was built based on the random forest machine learning and classification algorithm that separate driver and passenger genes mutation by 0.78 accuracy based on Matthews Correlation Coefficient.
MATERIALS AND METHODS

DATA SOURCE
Variant annotated datasets (VCF) were obtained from eight patients (patient identification: C187, C194, C273, C373, C404, C414, C449, C474) involved in the CRC patient genome sequencing project led by UKM Medical Molecular 3097 Medicine Institute (UMBI). Illumina Hiseq (30× coverage) was used for the sequencing and Gene Analysis Toolkit (GATK) was used in variant calling.
PREDICTION OF CRC DRIVER GENE USING BIOINFORMATICS TOOLS
Data were filtered by selecting all variants that occur at the exonic region as they are required as input in both tools. In iCAGES, the analysis was performed via http:// icages.wglab.org/ using hg19 as a reference genome. The required input format consists of the information on the chromosome, coordinates, references and alternate nucleotides. The output for the driver genes prediction consists of a list of genes with radial SVM score, funseq, cnv, phenolyzer and iCAGES gene score. As this analysis was focused on the nonsynonymous variants that occur at the coding region, the funseq and cnv scores were set at 0 and not included in the driver genes prediction. Predicted driver genes with gene score more than 0.11 were selected for the comparison with CGI results. CGI analysis was performed on https://www. cancergenomeinterpreter.org and colon adenocarcinoma was selected as a reference for the cancer type. The input files must include all information on the chromosomes, coordinates and nucleotide changes. The genes that are stated as a driver should consist of tumor suppressor genes where loss of function is detected and oncogenes which gain of function is likely to be occurred in certain variants. In this analysis, consensus results from both tools were chosen and considered as highly confidence predicted driver genes (HCDG) (Figure 1 ).
PATHWAY ANALYSIS
KEGG MAPPER in combination with the information obtained from the bibliomic search were applied in identifying all pathways related to the predicted driver genes (Figure 2) . Pathway mapping was performed using relevant KEGG pathway as a template in mapping the genes and to visualize the pathways that are likely to be affected by the driver genes was done using Cytoscape ver 3.6.0. Gene symbol of unique driver genes were set as an input in KEGG Mapper and the results were downloaded in KGML format for visualization.
RESULTS AND DISCUSSION CANCER DRIVER GENES PREDICTION
The consensus predicted genes obtained from iCAGES and CGI were named as high confidence driver genes (HCDG). Forty-four HCDG were identified using our approach (Table  1) . With this approach too, we have identified some genes that previously have not been listed in TCGA COADREAD and CGC Colorectal cancer genes dataset and have not been previously reported to be associated with colorectal cancer. Those genes were NCOR2, STAG2, PTPN12, TSC2, MYH9, NCOR1, PTCH1, ATF2 and ERBB3. These genes are potential candidates for newly identified colorectal cancer driver genes.
PATHWAYS ASSOCIATED WITH PREDICTED DRIVER GENES
Nonsynonymous variants that occurred at the exonic region were selected as an input for iCAGES and CGI. Predicted driver genes from both tools were named as HCDG (high confidence driver genes) and their respective pathways were identified from KEGG database and literature (Table 2 ). FIGURE 1. Selection of high confidence driver genes (HCDG) was based on the consensus result by iCAGES and CGI FIGURE 2. A flowchart for the prediction of colorectal cancer driver genes Continued TABLE 2 A total of 21 pathways have been identified related to the predicted CRC driver genes (Table 3 ). The information on the pathways where these genes were involved were obtained from KEGG database and literature searching. The result has suggested the involvement of driver genes in dysregulating the multiple pathways causing to the colorectal cancer carcinogenesis. The highest number of pathways might be dysregulated by driver genes were found in patient C474, followed by patient C414 and patient C373.
P53 signaling pathway shows positive signal of perturbation that affects 7 out of 8 patients in this study. Genes TP53, CHEK2 and TSC2 are predicted to drive colorectal carcinogenesis and related with p53 signaling pathway. Gene TP53 activated by CHEK2, CHEK1 and ATM to regulate various cell activities, meanwhile, TSC2 regulated by TP53 to inhibit mTOR signaling pathway (Figure 3) . Activation of mTOR signaling pathway will lead to increase in cell proliferation (Harris & Levine 2005; Li et al. 2015; Shao et al. 2001) .
Driver gene NCOR1 was found in the endocrine resistance pathway were predicted to be dysregulated in six patients (C187, C194, C373, C404, C414, and C474). In normal condition, NCOR1 forms a complex with ESR1 to inhibit the genes that involved in cell proliferation (Figure 4) .
Driver genes such as KRAS, NTRK1, ERBB3, ATF2, ERBB4, and HSP90AB1 were found in patient C273, C404, C414, C449, and C474 and they were involved in Phosphoinositide 3-kinase-AKT (PI3K-AKT) pathway ( Figure 5 ). PI3K-AKT signaling pathway is involved in mechanisms of growth stimulation, increase cellular proliferation and reduce apoptosis. Crucial component in PI3K-AKT is AKT3 is linked with driver gene, TSC2 regulator of mammalian target of rapamycin (mTOR) signaling pathway. mTOR signaling pathway has role in cell growth and proliferation.
MAPK signaling pathway was predicted as one of the highly dysregulated pathways in patient C273, C404, C414, C449, and C474. Three genes were involved in this pathway, i.e. BRAF, ERBB3, and MAP3K1. ERBB3 encodes a member of RTK (Receptor Tyrosine Kinase) and RTK activation initiates MAPK signaling pathway which then leads to the activation of another key signaling molecules i.e. Ras, which was encoded by KRAS gene. BRAF encodes for B-Raf protein; one of regulator sin MAPK-ERK signaling pathway that involved in cell proliferation and differentiation whilst MAP3K1 encodes for MEKK1 protein which is a key regulator in the MAPK-JNK signaling pathway. MEKK1 regulates proliferation, differentiation and inflammation (Fang & Richardson 2005; Ma et al. 2014 ).
CONCLUSION
From this study, 44 unique driver genes have been predicted in eight Malaysian colorectal cancer patients through extensive customized bioinformatics analysis along with the identification of 21 unique pathways that were found to be related with those driver genes. Amongst the identified pathways, that potentially perturbed driven by mutation of regulators are p53 signaling, PI3K-AKT, MAPK and endocrine resistance were predicted to be potentially perturbed driven by the mutation of regulators. Prediction of cancer driver genes will give detailed insight on the mechanisms of cancer development and a crucial step for targeted therapy process. 
